knowledge -WSS

knowledge

author：hotspot 2025-09-30 23:39:28 - browse：2552

Editor’s note: A recording of the event is embedded below.

Several biosimilar versions of Humira, which for years has been the world’s best-selling medicine, entered the U.S. market over the past year. What has that meant for insurance coverage and the way drugmakers are marketing these medicines? Join leading experts to discuss the impact on the industry and patients.

Sponsor introduction

Thomas Newcomer, vice president and head of U.S. market access, Samsung Bioepis (sponsor)

Featured speakers

Chris M. Brown, president, McAteer
Michael Gonzales, independent health care consultant, Michael Gonzales, LLC; former national and regional account director, AbbVie
Fran Gregory, MBA, PharmD, vice president of emerging therapies, Cardinal Health
Ed Silverman, Pharmalot columnist, senior writer, STAT (moderator)

WSS

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

STAT Executive Editor Rick Berke on STAT's 8th birthday

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

AI used to predict Covid

Extreme heat events are a public health emergency

Extreme heat events are a public health emergency

focus

knowledge

Sponsor introduction

Featured speakers

Sponsored By

Wikipedia

United colonoscopy coverage change 'may cost lives,' doctors say

Heat waves linked to early deliveries, preterm births in new study

Sports medicine is finally prioritizing gender equality

UCSF medical school apologizes for unethical prisoner experiments

Affirmative action in medical school literally saved lives

STAT Executive Editor Rick Berke on STAT's 8th birthday

Drug repurposing or repositioning? The language matters

FDA approves potent Eli Lilly obesity drug, Zepbound

Moonlake's readout produced a cash windfall. Risks remain

Abortion clinic in Cancun will cater to Americans

entertainment

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Study: New antibiotic targets gonorrhea as well as last existing drug

Will General Catalyst be the first of many hospital takeovers?

Childbirth

Sanofi CEO defends move to abandon profit guidance, boost research

Adam's Biotech Scorecard: Do Sarepta's exon

explore

focus

hotspot

focus